Apple Inc. (AAPL.US) is in talks with Silicon Valley startup PrismML, which claims it can shrink large AI models enough to run directly on iPhone devices, CNBC reported.

PrismML CEO Babak Hassibi said Apple and other companies are evaluating its models and testing speed, energy efficiency and performance on devices.

PrismML on Tuesday (14th) publicly released a compressed version of BABA-W (09988.HK)'s open-source Qwen model, saying it reduced the model size from about 54GB to less than 4GB, enabling its 27B parameters to run on iPhone 15 or newer models.

However, Hassibi disclosed that discussions with Apple remain at a very early stage, and the final direction is still unclear, although he said that things are progressing well. Apple has not given immediate response.
~

AASTOCKS Financial News
Website: www.aastocks.com

• As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS and a positive OS trend compared with pembrolizumab plus pemetrexed and platinum-based chemotherapy.
• Focusing on the particularly challenging first-line treatment for PD-L1-negative non-squamous NSCLC population, the introduction of a TROP2 ADC to a PD-1 mAb not only delivers ADC's precise targeting and killing of tumor cells, but also activates the immune microenvironment through their synergetic mechanisms. This strategy is expected to unlock the therapeutic potential of the PD-1 mAb in patients with PD-L1-negative or limited immune responses, breaking this therapeutic bottleneck.
• Following the meeting of the primary endpoint in the Phase III OptiTROP-Lung05 study for first-line PD-L1-positive NSCLC, the positive results were achieved in another Phase III trial of sac-TMT plus pembrolizumab, providing robust clinical evidence supporting the expansion of this combination regimen to a broader first-line NSCLC population.

CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®), in combination with MSD's^[1] anti-programmed cell death protein 1 (PD-1) therapy KEYTRUDA^®[2] (pembrolizumab) as a first-line treatment for programmed death-ligand 1 (PD-L1)-negative locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) has met its primary endpoint of progression‑free survival (PFS) at a prespecified interim analysis. This is the world's first Phase III clinical study of an ADC combined with an immune checkpoint inhibitor to meet its primary endpoint in the first-line treatment of driver gene‑negative and PD‑L1‑negative non-squamous NSCLC.

OptiTROP-Lung06 is a randomized, open‑label, multicenter Phase III clinical study evaluating the efficacy and safety of sac-TMT in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous NSCLC who have PD-L1 tumor proportion score (TPS) <1%. The primary endpoint of the study was PFS assessed by blinded independent central review (BICR); secondary endpoints included overall survival (OS), safety and others. At a pre-specified interim analysis, the sac-TMT combined with pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in PFS compared with pembrolizumab combined with pemetrexed and platinum-based chemotherapy, and a positive trend in OS was also observed. The safety profile of sac-TMT combined with pembrolizumab was consistent with that observed in previously reported studies, and no new safety signals were observed. The Company plans to communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China based on the results of this sac‑TMT study.

Previously, the Phase III registrational OptiTROP-Lung05 study of sac-TMT in combination with pembrolizumab as first-line treatment for PD-L1-positive NSCLC had successfully met its primary endpoint, supporting the submission of a new indication application to the CDE. The findings of the OptiTROP-Lung05 study were presented as an oral report at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet. The positive results from the OptiTROP-Lung06 study mark the further expansion of sac-TMT plus immunotherapy into the PD-L1-negative population in first-line non-squamous NSCLC, providing clinical support for this combination strategy to cover a broader first-line NSCLC population and are expected to drive the optimization of first-line treatment landscape for driver gene-negative non-squamous NSCLC.

Professor Caicun Zhou, National Lead Principal Investigator from Shanghai East Hospital, Tongji University, said: "For patients with driver gene‑negative and PD‑L1‑negative NSCLC, immunotherapy combined with chemotherapy remains the current standard first-line treatment and has improved patient outcomes to some extent. However, long-term survival benefit remains limited. The achievement of positive results in the Phase III OptiTROP-Lung06 study represents an important breakthrough in the first-line treatment of PD-L1-negative NSCLC. These results not only provide robust clinical evidence supporting the 'ADC plus immunotherapy' strategy of sac-TMT in combination with pembrolizumab, but also have the potential to offer these patients a new first-line treatment option beyond the current standard of care, with the promise of improved survival outcomes."

Dr. Michael GE, CEO of Kelun-Biotech, stated: "We are delighted to see that sac-TMT combined with pembrolizumab has achieved exciting positive results compared with immunotherapy plus chemotherapy in the first-line treatment of patients with PD-L1-negative NSCLC. This ADC plus immunotherapy regimen has previously demonstrated superior efficacy over immunotherapy monotherapy in patients with PD-L1-positive NSCLC. The positive results of both the OptiTROP-Lung05 and OptiTROP-Lung06 studies confirm the strong synergetic effect of sac-TMT combined with pembrolizumab, supporting the potential of this combination regimen to benefit the broad first-line NSCLC population and bringing new treatment opportunities to patients with different PD-L1 expression levels."

Sac-TMT is currently being evaluated in ten registrational studies in lung cancer, including five registrational studies in China and five global multicenter Phase III studies.

About sac-TMT(佳泰莱^®)
Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

• 作為頭對頭對比一線標準治療「免疫+化療」的III期臨床研究，OptiTROP-Lung06證實了以蘆康沙妥珠單抗(sac-TMT)替代傳統培美曲塞/鉑類化療具有顯著優勢——蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比帕博利珠單抗聯合培美曲塞及鉑類化療，PFS顯著延長並觀察到OS積極獲益趨勢
• 聚焦一線治療更具挑戰性的PD-L1陰性非鱗狀NSCLC人群，在PD-1單抗的基礎上引入TROP2 ADC，不僅發揮了ADC精準靶向殺傷的作用，更通過協同效應激活了免疫微環境，有望釋放PD-1單抗在PD-L1陰性/免疫應答不足人群中的潛力，打破該人群的治療瓶頸
• 繼一線治療PD-L1陽性NSCLC的 OptiTROP-Lung05 III期研究達成主要終點後，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗治療方案取得又一項III期研究陽性結果，為這一聯合方案擴展至更廣泛的一線NSCLC人群奠定堅實的臨床證據基石

成都2026年7月15日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」 6990.HK)宣佈，公司靶向人滋養細胞表面抗原2(TROP2)的抗體偶聯藥物(ADC)蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊^®)聯合帕博利珠單抗(可瑞達^®[1]，默沙東^[2]的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體-1(PD-L1)陰性的局部晚期或轉移性非鱗狀非小細胞肺癌(NSCLC)的III期臨床研究(OptiTROP-Lung06)，在預設的期中分析中，經獨立數據監查委員會(IDMC)確認達到無進展生存期(PFS)主要終點。這是全球首個ADC聯合免疫檢查點抑制劑在一線治療驅動基因陰性、PD-L1陰性非鱗狀NSCLC上達到主要終點的III期臨床研究。

OptiTROP-Lung06是一項隨機、開放性、多中心III期臨床研究，旨在評估蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比化療聯合帕博利珠單抗一線治療PD-L1腫瘤比例分數(TPS)<1%的局部晚期或轉移性非鱗狀NSCLC患者的有效性和安全性。研究主要終點為由盲態獨立中心評審(BICR)評估的PFS，次要終點為總生存期(OS)、安全性等。在預設的期中分析中，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗療法與帕博利珠單抗聯合培美曲塞及鉑類化療相比在PFS方面顯示出統計學意義和臨床意義的顯著改善，OS方面亦觀察到獲益趨勢。安全性方面，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗的安全性特徵與既往研究報告一致，未觀察到新的安全性信號。公司計劃就蘆康沙妥珠單抗(sac-TMT)該研究結果，與中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)進行溝通交流。

此前，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療PD-L1陽性NSCLC的III期註冊性研究(OptiTROP-Lung05)已達到主要終點並基於此研究向CDE提交了新增適應症上市申請；OptiTROP-Lung05研究成果已於2026年美國臨床腫瘤學會(ASCO)年會以口頭報告形式發佈，並同步發表於國際知名期刊《柳葉刀》(The Lancet)。此次OptiTROP-Lung06研究再獲陽性結果，標誌著蘆康沙妥珠單抗(sac-TMT)聯合免疫治療在一線非鱗狀NSCLC中進一步拓展至PD-L1陰性人群，為該聯合策略覆蓋更廣泛一線NSCLC人群提供了臨床支持，並有望推動驅動基因陰性非鱗狀NSCLC一線治療格局的優化升級。

全國牽頭研究者、同濟大學附屬東方醫院周彩存教授表示：「目前，針對驅動基因陰性、PD-L1陰性NSCLC患者，免疫聯合化療作為一線標準治療雖在一定程度上改善了患者預後，但其長期生存獲益仍然有限。此次OptiTROP-Lung06 III期已達到主要終點，是PD-L1陰性NSCLC一線治療領域的一項重要突破，該研究不僅為蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗這一『ADC+IO』方案提供了堅實的循證醫學證據，更有望為這類患者帶來超越當前標準治療的全新一線選擇，實現更優的生存獲益。」

科倫博泰首席執行官葛均友博士表示：「很高興看到蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比免疫聯合化療在一線治療PD-L1陰性NSCLC患者中取得令人振奮的陽性結果，該『ADC+IO』方案此前已在PD-L1陽性NSCLC患者中展現出優於免疫單藥的突出療效。OptiTROP-Lung05、OptiTROP-Lung06兩項研究相繼告捷，充分印證了蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗具有強大的協同效應，有望實現一線NSCLC人群的廣泛覆蓋，為不同PD-L1表達水平的患者帶來治療希望。」

截至目前，蘆康沙妥珠單抗(sac-TMT)正在中國及全球範圍內開展10項針對肺癌的註冊性臨床研究，包括5項中國註冊性研究，以及5項全球多中心III期研究。

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)

作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2 ADC，針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單抗沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑有效載荷pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療（其中至少1種治療針對晚期或轉移性階段）的不可切除的局部晚期或轉移性三陰性乳腺癌(TNBC)；2)經表皮生長因子受體-酪氨酸激酶抑制劑(EGFR-TKI)和含鉑化療治療後進展的表皮生長因子受體(EGFR)基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-)BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定(BTD)。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。蘆康沙妥珠單抗(sac-TMT)的新增適應症上市申請已獲NMPA受理，用於聯合帕博利珠單抗(可瑞達^®)一線治療PD-L1 TPS≥1%的EGFR基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC，並被納入優先審評審批程序。目前，科倫博泰已在中國開展9項註冊性臨床研究。默沙東已啟動17項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30餘個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個項目處於新藥上市申請(NDA)階段，10餘個項目正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平台OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。瞭解更多，請訪問https://www.kelun-biotech.com/。 

SHENZHEN, China, July 14, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited financial results for the second quarter of 2026 before the U.S. market opens on Tuesday, August 11, 2026.

TME's management will host a Tencent Meeting Webinar on Tuesday, August 11, 2026, at 7:00 A.M. Eastern Time or 7:00 P.M. Beijing/Hong Kong Time on Tuesday, August 11, 2026, to review and discuss the Company's business and financial performance.

For participants who wish to join the Tencent Meeting Webinar, please complete online registration in advance using the links provided below. Upon registration, each participant will receive an email with webinar access information, including meeting ID, meeting link, dial-in numbers, and a unique attendee ID to join the webinar.

Participant Online Registration

Chinese Mainland^[1]: https://meeting.tencent.com/dw/taPIQDShxiVQ
International:             https://voovmeeting.com/dw/taPIQDShxiVQ

A live and archived webcast of the webinar will also be available at the Company's investor relations website at https://ir.tencentmusic.com/.

^[1] Chinese Mainland, for the purpose of this announcement only, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region of the People's Republic of China and Taiwan

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.

Investor Relations Contact
Tencent Music Entertainment Group
[email protected]  
+86 (755) 8601-3388 ext. 885034

HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cadonilimab is the world's first PD-1/CTLA-4 bispecific antibody developed by Akeso.

The study is being led by Dr. Yelena Janjigian, a globally renowned expert in gastrointestinal malignancies at MSKCC. It is now actively enrolling patients across the United States.

This Phase II study will generate robust clinical evidence to support the future initiation of an international multicenter Phase III trial of the cadonilimab combination regimen for the perioperative treatment of GC/GEJ adenocarcinoma.

Cadonilimab and ivonescimab, as first-in-class bispecific antibodies with breakthrough global clinical value, have garnered significant attention and recognition from the international medical community. These innovative IO 2.0 therapies are increasingly favored by global partners as the preferred backbone for combination regimens and novel treatment paradigms across a wide range of cancers. Their global therapeutic value continues to be scientifically explored and realized through ongoing clinical data and new studies.

Building on cadonilimab's unique dual-target synergistic mechanism, this Phase II study is supported by strong evidence from the Phase III COMPASSION-15 trial and previous Phase II neoadjuvant studies in gastric/GEJ adenocarcinoma.

Gastric cancer is the fifth most common malignancy worldwide, with nearly one million new cases annually. For patients with locally advanced, resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, standard perioperative FLOT chemotherapy achieves a 3-year overall survival rate of only 48%. Although the addition of PD-1 inhibitors to FLOT has become the new standard of care, the pathologic complete response (pCR) rate remains limited at approximately 19%, and nearly one-third of patients experience disease recurrence or death within two years. Dual PD-1/CTLA-4 inhibition has shown limited benefit due to overlapping toxicities and increased early mortality. A significant unmet medical need persists for more effective and better-tolerated treatment options.

As the first approved bispecific antibody for cancer immunotherapy, cadonilimab has demonstrated breakthrough clinical benefits across multiple pivotal studies and is now widely used in clinical practice. More than 12 registrational or Phase III studies of cadonilimab are currently underway globally, including two international multicenter registrational/Phase III trials led by Akeso.

In addition, Akeso is collaborating with INOVIO to explore a novel combination regimen using INOVIO's DNA-based therapy for glioblastoma (GBM) at Dana-Farber Cancer Institute and Mass General Brigham. The Company continues to accelerate the global development of cadonilimab through strategic partnerships with leading therapeutics and institutions.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Counterpoint Research's latest report showed that global smartphone shipments sank 11% in the second quarter, hitting the lowest level since 2013, as prolonged memory chip shortages pushed up handset prices and suppressed demand.

During the period, iPhone shipments of Apple Inc. (AAPL.US) grew 3%, giving the company a global market share of 20%. Samsung regained the top spot with a 24% market share and recorded the strongest growth among the top five brands, driven by robust sales of its flagship Galaxy S26 series. XIAOMI-W (01810.HK) ranked third with a 12% market share, followed by OPPO (11%) and vivo (8%).
~

AASTOCKS Financial News
Website: www.aastocks.com

Due to substandard product quality, NVIDIA Corporation (NVDA.US) may stop cooperating with VGT (02476.HK) after evaluation, involving order amounts of RMB5 billion, according to market talks.

VGT issued an announcement to clarify that recent online rumors regarding the company's products, market share and project progress were seriously inconsistent with facts. The company emphasized that it is a long-term strategic partner of leading domestic and overseas AI clients, and has always regarded quality and safety as its lifeline while strictly managing operations according to client standards.

VGT stated that demand for AI-related PCB products remains strong, with orders on hand continuing to grow, while production and shipments are operating normally. Orders from major clients continue to increase, and the company has maintained close communication with core clients. Iterative products jointly developed through cooperation are progressing smoothly, while some clients have already released long-term demand projections for 2027 to 2028. Management expressed full confidence in subsequent production operations and profit realization.

The group said false rumors spread through online platforms and WeChat groups have adversely affected its reputation and normal business operations, seriously misleading investors. The company will reserve the right to pursue liabilities through legal channels.
~

AASTOCKS Financial News
Website: www.aastocks.com

Iran announced the indefinite closure of the Strait of Hormuz, while the US military attacked Iran for the fourth time within a week, sending international oil prices up more than 3%.

Futures for the three major US stock indices were mixed. DJIA futures edged up 6 points, while S&P 500 futures and Nasdaq futures lost 0.35% and 1.15%, respectively. South Korean stocks plunged 9%, while US chip and memory stocks came under pressure in pre-market trading. Micron Technology, Inc. (MU.US) dived 5.5% pre-market. Sandisk Corporation (SNDK.US), Western Digital Corporation (WDC.US) and Seagate (STX.US) shed 4.8-7% pre-market. Marvell Technology, Inc. (MRVL.US), Advanced Micro Devices, Inc. (AMD.US), Intel Corporation (INTC.US), QUALCOMM Incorporated (QCOM.US) and NVIDIA Corporation (NVDA.US) faded 1.9-3.1% pre-market.

Major Asia-Pacific stock markets generally declined today (13th). China's three major A-share indices closed down between 2.1% and 3.5%. Hong Kong stocks gained 38 points, or less than 0.2%, to close at 24,213 points, with turnover of HKD309.515 billion. Japan's Nikkei closed down 1,315 points, or 1.9%, at 67,242. South Korea's Kospi closed down 669 points, or 8.95%, at 6,806, marking a more than two-month low and triggering the seventh circuit breaker this year. Samsung Electronics plunged 10.7%, while SK Hynix tumbled 15.4%, marking the stock's biggest single-day decline on record. SK Hynix ADR, which was listed in the US last Friday, closed at USD168.01, 12.8% above its offer price. UBS previously issued a report recommending buying SK Hynix ADR while short-selling its listed South Korean shares.

European stocks were mixed in early Monday trading. The pan-European STOXX 600 fell 0.2% to 639.82. The UK's FTSE 100 edged down 0.1% to 10,486. France's CAC dipped 0.15% to 8,326. Germany's DAX added 0.1% to 25,087. Italy's FTSE MIB hiked 0.1% to 52,660. Spain's IBEX 35 sank 0.2% to 19,352.
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Foundry Chief Engineer James Kim said Samsung Electronics has completed the design of Tesla (TSLA.US)'s AI5 autonomous driving system chips, which will adopt Samsung's latest 2-nm process technology and are expected to begin production soon at its Texas foundry plant.

The chips are currently in the tape-out stage, marking the finalization of the design and the start of engineering sample production.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, July 13, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announced that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), has signed a tripartite Memorandum of Understanding (MOU) with Advantech Co., Ltd. ('Advantech'; Stock Code 2395.TW), a global leader in IoT intelligent systems and embedded platforms, and YDCare, a medical nursing brand under New Frontier Group. Under the MOU, KLN Medical will be the sole distributor of Advantech's iWard smart ward solutions ('iWard') for the Hong Kong market. The partnership aims to synergise the three parties' expertise across smart healthcare technology, clinical application and medical supply chain management to support the digital transformation of Hong Kong's healthcare system and promote the application and development of advanced healthtech.

KLN Medical will leverage its combined strengths in healthcare supply chain management, technical capabilities and after-market support to provide medical institutions with one-stop solutions covering equipment delivery, after-sales technical support, maintenance services and system implementation co-ordination, fully supporting the smooth deployment and long-term development of iWard in Hong Kong. Through iWard's integration of patient information, clinical workflows and medical equipment and seamless connection with the existing information systems of medical institutions, together with YDCare's expertise in clinical application, the three parties will work together to help healthcare teams enhance clinical collaboration efficiency and ward operation management, drive the development of smart wards and the digitalisation of clinical workflows and create greater value for healthcare professionals and patients.

Samuel Lau, Managing Director - Integrated Logistics of KLN, said, "We are pleased to enter this tripartite partnership with Advantech and YDCare, which marks an important milestone for our expansion into the smart healthcare sector. With our professional expertise, extensive healthcare logistics network and commitment to service excellence, we will provide Hong Kong's medical institutions with efficient and reliable supply chain solutions."

Jackson Hsu, PD Head of Advantech, said, "The iWard solutions have gained recognition in multiple Asian healthcare markets including the Chinese Mainland, Thailand and Japan. We look forward to introducing this proven and reliable technology to Hong Kong in collaboration with KLN Medical and YDCare, with a view to advancing medical digitalisation. This will provide efficient operational support for frontline medical professionals and enhance the patient care experience."

Serena Xie, Founder and CEO of YDCare, said, "YDCare has been dedicated to providing home nursing care services for a decade and is one of the pioneers in home-based healthcare in Hong Kong. With our clinical perspective, professional experience and nursing best practices, we will integrate patient data with the intelligent systems. We hope this collaboration will help more medical institutions optimise nursing workflows and further improve the quality and safety of patient care."

Looking ahead, KLN Medical will continue to partner with industry leaders to deliver innovative medical technologies and promote a smarter healthcare ecosystem. 

-End-

About KLN Logistics Group Limited (Stock Code 0636.HK)

KLN is an Asia-rooted, global 3PL delivering customer-centric, end-to-end supply chain solutions that connect markets and power global trade, as a trusted partner to many of the top 100 global brands and Fortune Global 500 companies across a wide spectrum of industries. With a presence across 58 countries and territories, KLN offers integrated logistics, international freight forwarding, e-commerce and industrial project logistics solutions. KLN has been the global No. 1 Trans-Pacific NVOCC from Asia to the US since 2023 and ranks No. 20 among Global 3PLs (Armstrong & Associates, 2026). Listed on the Hong Kong Stock Exchange, KLN generated revenue* of over HK$56 billion in 2025 and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index. Learn more at www.kln.com

* For continuing operations only

About KLN Medical Limited

KLN Medical is dedicated to advancing healthcare in Hong Kong and Southeast Asia by delivering innovative medical technologies that improve patient outcomes. In collaboration with world-renowned partners, KLN Medical ensures that healthcare professionals have access to the latest advancements, driving excellence across the continuum of care. As a member of the KLN Group, KLN Medical focuses on the reliable distribution of high-quality medical devices and solutions. Its multidisciplinary team brings deep expertise across key areas including cardiovascular care, rehabilitation, hospital and clinic support, engineering, marketing, business development, regulatory affairs and quality assurance, customer service, and operations. Website: www.medical.kln.com

About Advantech Co., Ltd

Advantech is a global leader in IoT intelligent systems and embedded platforms, with the corporate vision of "Enabling an Intelligent Planet." To embrace the trends of edge computing and artificial intelligence, Advantech fully deploys its sector-driven strategy and focus on Edge Computing and Edge AI, targeting five key markets: Edge Intelligence Systems, Manufacturing, Energy and Utilities, iHealthcare, and iCity Services & iRetail. In the meantime, Advantech is enhancing its global presence and core competitiveness by integrating its Edge Computing hardware platform, the WISE-IoT software platform, and sector-specific Edge AI solutions with domain expertise. The integration will form an "Orchestration" model for seamless industrial chain connections, benefiting both partners and clients. Advantech is also working with business partners to co-create business ecosystems that accelerate the goal of industrial intelligence. Website: https://www.advantech.com/zh-tw

About YDCare

YDCare is the flagship home care brand of New Frontier Group. Backed by the Group's premium medical resources, YDCare continuously enhances its personalised, comprehensive, and tiered professional services to meet the diverse home care needs of both the elderly and children in China. Led by senior nursing experts and a multidisciplinary team, its Hong Kong & International business line is dedicated to extending hospital-grade safety standards and clinical workflows into the home environment. The platform delivers a one-stop service encompassing medical nursing, daily care, home rehabilitation, palliative and end-of-life care, and medical equipment rental. Notably, YDCare pioneers advanced medical technologies in Hong Kong's home settings, including Negative Pressure Wound Therapy (NPWT) and Home Parenteral Nutrition (HPN), enabling patients to recover safely in familiar surroundings while effectively reducing unnecessary hospitalisations and commutes. Website: www.ydcarehk.com